Welcome to our dedicated page for Elicio Therapeutics news (Ticker: ELTX), a resource for investors and traders seeking the latest updates and insights on Elicio Therapeutics stock.
Elicio Therapeutics reports developments as a clinical-stage biotechnology company developing cancer immunotherapies. Company news centers on its proprietary Amphiphile, or AMP, technology, the ELI-002 program, and immunotherapy work for mKRAS-positive cancers including pancreatic ductal adenocarcinoma, colorectal cancer, lung cancer, and other KRAS-driven tumors.
Recurring updates also include clinical and regulatory disclosures, operating and financial results, healthcare-conference presentations, shareholder voting and governance matters, capital-structure actions, and Nasdaq inducement stock option grants under the company’s 2024 Inducement Incentive Award Plan.
Elicio Therapeutics (Nasdaq: ELTX) reported Q1 2026 results and clinical updates. The Phase 2 AMPLIFY-7P primary disease-free survival analysis of ELI-002 7P in post-resection mKRAS PDAC is expected mid-2026, with fewer progressions and deaths than projected.
Q1 R&D was $6.8M, G&A $3.8M, net loss $11.8M ($0.65/share). Cash was $14.9M on March 31, plus $13.0M raised via ATM, supporting operations into Q4 2026.
Elicio Therapeutics (Nasdaq: ELTX) will present at the Bank of America Healthcare Conference in Las Vegas on May 14, 2026 at 12:20 PM ET.
Presenters include CEO Robert Connelly, CMO Christopher Haqq, CSO Pete DeMuth, and CSFO Preetam Shah. A live webcast and 90-day replay are available via the company’s Events page. 1×1 meetings are arranged through Bank of America representatives.
Elicio Therapeutics (Nasdaq: ELTX) announced on April 16, 2026 that it granted 21,210 inducement stock options to a new employee, approved by the Compensation Committee under the 2024 Inducement Incentive Award Plan.
The options have a $11.78 per-share exercise price (Nasdaq closing price on April 15, 2026) and vest over four years: 25% on the first anniversary of employment, then monthly thereafter, subject to continued service and Nasdaq Listing Rule 5635(c)(4).
Elicio Therapeutics (Nasdaq: ELTX) granted an aggregate of 1,600 inducement stock options on March 16, 2026, to a newly hired employee under the 2024 Inducement Incentive Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have a strike price of $12.16 (Nasdaq closing price on March 16, 2026) and vest over four years with 25% vesting after one year and monthly ratable vesting thereafter, subject to continued service.
Elicio Therapeutics (Nasdaq: ELTX) reported 2025 results and clinical updates on March 12, 2026. The company expects an event-driven primary DFS analysis in 1H 2026 from the randomized Phase 2 AMPLIFY-7P trial in resected mKRAS PDAC and remains blinded to efficacy outcomes.
Notable 2025 financials: R&D $24.9M, G&A $12.8M, net loss $39.6M, and $18.6M cash with runway into Q3 2026; antigen spreading and T-cell durability were reported in December 2025.
Elicio Therapeutics (Nasdaq: ELTX) announced that CEO Robert Connelly and CSO Pete DeMuth will present at the TD Cowen 46th Annual Health Care Conference in Boston, March 2-4, 2026. The company presentation is scheduled for March 4, 2026 at 1:10 PM ET.
According to Elicio, a live webcast and a 90-day replay will be available on the company Events page for investors who cannot attend in person.
Elicio Therapeutics (Nasdaq: ELTX) granted an aggregate of 30,300 inducement stock options on February 17, 2026, to a newly hired employee under its 2024 Inducement Incentive Award Plan.
The options have an exercise price of $8.59 per share (Nasdaq close on Feb 17, 2026) and vest over four years with 25% vesting after one year and monthly vesting thereafter, subject to continued service.
Elicio Therapeutics (Nasdaq: ELTX) announced on January 16, 2026 that on January 15, 2026 it granted an aggregate of 22,400 inducement stock options to two new employees under the 2024 Inducement Incentive Award Plan as permitted by Nasdaq Listing Rule 5635(c)(4). The grants were approved by the Compensation Committee and set the exercise price at $7.81 per share, the Nasdaq closing price on the grant date. The options vest over four years with 25% vesting on the first anniversary of each employee’s start date and the remainder vesting ratably each month thereafter, subject to continued service.
Elicio Therapeutics (Nasdaq: ELTX) announced on December 16, 2025 that on December 15, 2025 it granted an aggregate of 157,193 inducement stock options to three new employees under the 2024 Inducement Incentive Award Plan.
The option exercise price is $8.52 per share, equal to the Nasdaq closing price on December 15, 2025. Grants were approved by the Compensation Committee and issued as inducements under Nasdaq Listing Rule 5635(c)(4). The awards vest over four years: 25% on the first anniversary of each start date, then the remainder vesting ratably monthly subject to continued service.
Elicio Therapeutics (Nasdaq: ELTX) reported that analysis from a subset of the Phase 2 AMPLIFY-7P trial showed antigen spreading beyond targeted mKRAS antigens after ELI-002 7P treatment.
Key results: 87% (13/15) of evaluated patients showed T cell responses to non-mKRAS neoantigens; among 90 treated patients, 99% (89/90) had mKRAS T cell responses; median fold change for antigen spreading in Phase 2 was 10.6x and 90% of assessed patients showed responses in both CD4 and CD8 T cells.